Exhibit 99.1

ACCESS PHARMACEUTICALS

Moderator: Donald Weinberger
October 14, 2005
9:00 am CT


Operator: Ladies and gentlemen, thank you for standing by.  Welcome to the
Announce Sale of Oral Care Business conference call.

During the presentation, all participants will be in a listen-only mode.
Afterwards, we will conduct a question-and-answer session.

At that time, if you have a question, please press the 1 followed by the 4
on your telephone.

As a reminder, this conference is being recorded, Friday, October 14, 2005.

I would now like to turn the conference over to Mr. Donald Weinberger, Managing
Partner.  Please go ahead sir.

Donald Weinberger: Thank you (Susan).  I am Donald Weinberger, Managing Partner
of Wolfe, Axelrod, Weinberger Associates.

Welcome and good morning.  I welcome you to the conference call for Access
Pharmaceuticals update of recent developments and future outlook.

A release was issued late Wednesday afternoon discussing the sale of its oral
care business to Uluru Inc.  If you do not have a copy of that release and
would like one, please call my office immediately at 212-370-4500.

Due to time constraints today, we would like to ask that you limit the number of
questions you ask to two and we would like to conclude the call in approximately
40 to 45 minutes.

If there are any open items or unanswered questions, please feel free to email
me at don, D-O-N, @wolfeaxelrod; that's don@wolfeaxelrod.com.  Wolfe Axelrod
is spelled W-O-L-F-E A-X-E-L-R-O-D, dot com.

And I will pass those emails on to management of Access Pharmaceuticals.  Before
I turn the call over to Rosemary Mazanet, CEO, and Michael Flinn, Chairman, I'll
read to you the Safe Harbor statement as required by law.

This conference call contain statements that are forward-looking within the
meaning of Section 27a of the Securities Act of 1933, as amended, and that
involve risks and uncertainties, including, but not limited to statements
made relating to negotiation, to restructure, or outstanding convertible
notes which negotiations may not be successful or current steps being taken
to satisfy our cash needs, and our ability to achieve the
milestones relating to our oral care assets sold to Uluru Inc.

These statements are subject to numerous risks including, but not limited to
the uncertainties associated with our ability to raise funds to continue our
operation; our ability to sell assets; our ability to restructure our
convertible notes, research and development activities, clinical trials;
our ability to raise capital, the timing of and our ability to achieve
regulatory approvals dependent on others to market our licensed product,
collaborations, future cash flow, and timing and receipt of licensing a
milestone revenue, projected future revenue growth, and our ability to
generate near term revenues, our ability to develop products from our
platform technology; our ability to achieve licensing milestones; our
ability to repay our outstanding debt obligations; and other risks detailed
in the company's annual report on Form 10K for the year ended December 31,
2004, quarterly report on Form 10Q for the quarter ended June 30, 2005,
and other reports filed by us with the Securities and Exchange Commission.

At this time, I will turn the call over to Rosemary Mazanet.

Rosemary, please proceed.

Rosemary Mazanet: Good morning.  Thanks Don.  That was quite a -

Donald Weinberger:       Mouthful.

Rosemary Mazanet: "a mouthful, that's right.

Donald Weinberger: (Unintelligible).

Rosemary Mazanet: The last few months have been very challenging for the board
and management of Access Pharmaceuticals, as it went through a financial
restructuring that was well described in our most recent 10Q.  We appreciate
your support and patience through this period and we're very pleased to
bring you up to date today.

The plan we've outlined to refocus the company on oncology has been realized and
our balance sheet is much stronger.  We began an asset sale process a number of
months ago, as a way to properly maximize the potential of all of the
technologies under the Access Pharmaceuticals patent portfolio.

This process to sell our non-strategic assets received a good deal of interest
and we spoke with a number of potential buyers in the US and in Europe.
Following the receipt of offers, a decision was made to sell our oral care
business to Uluru, a private Delaware company for up to $20.6 million.

This sale includes our interest in Aphthasol, all OraDisc products, all
Residerm products, and all company assets related to those products.  In
addition, we have licensed to Uluru our nanoparticle hydrogel aggregate
technology which could be used for local drug delivery and (tissue filler)
in dental and soft tissue application.

The CEO of Uluru is Kerry Gray, the former CEO of Access Pharmaceuticals. And
in conjunction with this sale transaction, we received (a fairness) opinion
from a nationally recognized investment banking firm.

There are eight employees of Access that will be assumed by Uluru, and six
employees of Access who will remain.  A cost sharing of the leasing arrangements
for the shared space will go through a transition period until Uluru relocates
to the -  a new space.

At the closing of this agreement, we received $8.7 million.  In addition, at
the one year anniversary of the agreement, we may receive up to $3.7 million
and we will receive an additional $1 million within 24 months after closing
or earlier upon the achievement of milestones.

Additional payments of up to $7 million will be made upon the achievement
of certain additional milestones.

The upfront payment of this transaction has allowed Access to retire our $2.9
million of senior secured debt that was held by Cornell Capital, and the
various agreements relating to those notes.

In addition, the elimination of the manufacturing and regulatory costs, as
well as the required employees for those marketed products and product
candidates will allow Access to reduce our burn rate substantially.

We believe that we are in a much better position to manage the $8 million of
convertible debt remaining on the company's balance sheet which is currently
due.

Since this deal closed Wednesday evening, we've been in active discussions
with one of the debt holders, and it is our opinion that waiting until the
senior secured debt was retired, allows us to restructure or convert some or
all of the convertible debt with less dilution.

While this transaction places the company in a stronger financial position,
the board of directors and senior management are continuing to explore
strategic options for the company to support the continuation of our
exciting oncology programs.

Options still under consideration include equity financing, out-licensing of
technologies and development programs, a joint venture, or other strategic
alternatives.  We plan to engage in investment bank to assist us in the
exploration of these options.

I would now like to provide you with an update on our development programs.  As
you know, I'm very excited about our platinum polymer drug, AP5346, and it will
have its Phase I clinical data presented at the NCI-EORTC-AACR meeting in
November.  That actually is an annual meeting that is a mixture of the three
groups from Europe and the US and it's a rather new meeting, it's a little
different than the regular AACR meeting.

The data that will be shown; will show partial responses in patients with
melanoma and ovarian cancer.  To see partial responses in a small sample of
16 patients is very encouraging in a Phase I trial when most of the patients
were treated at a low dose.

Of note, the ovarian cancer patients have received prior platinum therapy
and had relapse before they responded to AP5346.  All of the toxicity seen
in this Phase I trial were typical for other platinum compounds that are
given without pre-medications to curb side effects and liberal intravenous
fluids.

In the current quarter, we plan to begin a Phase II trial in ovarian cancer
patients who have relapsed after first line platinum therapy.  Other
Phase II trials in different tumor types are being planned currently.

Now, to fill you in on the pipeline a little bit, the same polymer backbone
platform that we used in AP5346 can have the platinum exchanged for another
anticancer agent, and we have some exciting pre-clinical data demonstrating
the enhancement of efficacy by using this polymer delivery approach.

We will be evaluating which of these programs we will continue in formal
pre-clinical candidate testing.  We're also excited about continuing to
explore collaborations for our proprietary nanoparticle drug delivery
system for targeting therapeutics and diseases such as cancer and also
possibly rheumatoid arthritis.

This nanoparticle drug delivery technology allows for systemic delivery and
it's different from the aggregate hydrogel that has been licensed to Uluru.
The company has more than one nanoparticle drug delivery technology.

Okay, there's been an increased interest in the use of the nanoparticles for
delivering drugs to tumors following the approval earlier this year of a
Taxol nanoparticle formulation.  And - we have kept that proprietary
technology for this nanoparticle drug delivery system.

Our proprietary vitamin targeted technology is also another mechanism by
which we could provide enhanced delivery of nanoparticle formulation to
sites of disease.

Our Vitamin B12 oral drug delivery technology offers great promise to provide
oral dosage forms for active ingredients, such as proteins and peptides,
which currently can only be administered by injection.  Access already has
three ongoing collaborations in this area and is currently in discussion
with additional potential partners.

We remained listed on AMEX and we will be updating AMEX in the near future of
our plans to manage our outstanding debt and our plans to meet the continuing
listing requirements for AMEX.

We will update you more about our balance sheet and projected financials
after we have further information to report about our outstanding debt
situation.

Following the resolution of this convertible debt situation, the company
will consider options on how best to move the Access programs forward.

At this time, we - I'm going to invite Michael Flinn to participate in
answering the questions and we'll be happy to take your questions.

I'm going to ask (Susan) if she could line up the queue, please.

Operator: Ladies and gentlemen, if you'd like to register for a question,
please press the 1 followed by the 4 on your telephone.  You will hear a
three-tone prompt to acknowledge your request.

If your question has been answered and you would like to withdraw your
registration, please press the 1 followed by the 3.

If you're using a speakerphone, please lift your handset before entering
your request.

Our first question comes from the line of (Bill Dawkins) from
(Burlston Dawkins).  Please proceed with your question.

(Bill Dawkins): Good morning, Rosemary.

Rosemary Mazanet: Good morning.

(Bill Dawkins): I wanted to congratulate you first on the sale of these
business units.  I think, getting what - more than the market cap of the
company was over the past month or two, that's quite an achievement and
good job.

A couple of questions, could you -- only because I don't really understand
so much AB5346 -- could you first define the market size that drug will be
entering into?

And can you add a little cover - color to the - to a (JV) or a licensing
agreement or royalties or whatever in association with this drug going
forward?  Or maybe, what are your goals in respect to the goals of this drug?

Rosemary Mazanet: Okay, okay.

The - this is a platinum drug, as you know, and you know, we would assume
that this drug would be approvable for some indication once we complete all
of our clinical work.  Which indication we plan to go into in, you know,
for a registration strategy, and what indication we would plan to go into
ultimately for the market potential, you know, still needs to be worked out.

But, you know, this could be somewhere between, I think, you know, a) if it's
a ("me too") drug, okay, and we can't differentiate it extensively, then it
could be, you know, maybe -- and this is very conjectural -- it could be a
$300 million to $400 million drug.

If it's actually less toxic than oxaliplatin, which is a $2 billion drug,
then obviously, you know, we would hope that it could take a good bit of
that market.

Now with that, I want to remind you that, you know, this is still in very
early stage testing.  And you know, so far we're quite pleased, but, you
know, there is risk inherent in all of these development programs.

What I'd like to tell you about how we plan to move it ahead, is that, you know,
when we had an insecure financial position in over the last few months, you
know, any deal that we come to with would obviously be taking advantage of
that situation.

So we have talked to people about licensing possibilities but they frankly
haven't really, even with, you know, discounting the risk associated with
clinical drug development, haven't recognized what we think was the potential
value.

So that's why we haven't entered into any of those agreements, but we have
continued to work on the drug on our own, it's not as so we stopped working.
And you know, we're ready to start these trials.

So, you know, we've manufactured it over the summer and we're ready to start
trials and we are - have sort of - or dictating our own fate in a, you know,
we're continuing to collect data that we hope will continue to look attractive.

So my answer really about, you know, what we would expect to see in a licensing
deal or what we want going forward, is we would expect to see something that
would recognize what we believe is the real potential of the drug.

I hope you don't think that's a round-around answer, but, you know -

((Crosstalk))

Rosemary Mazanet: - it has to be a good offer.

(Bill Dawkins): Would it be an - would you probably go international before
domestic on that?  And secondly, and then I will let someone else ask a
question, is AP5346 the reason why you're at AKC?

Rosemary Mazanet: Well, I have been aware of this product candidate for a
while.  I had seen some of the data earlier when I was a consultant for the
company and I do think it's very exciting and I think that that's obviously
why I'm interested in having the company succeed.  You know, I think this is
a very promising candidate.

Your question about domestic and (ex-US), I think that we have talked quite
a bit about the fact that the Phase I data was obtained in Europe and we that
maybe getting Phase II trial started in Europe as well.

And the reason for that, just so you understand, is there is a lot of
competition right now for patients and for (centers) to do trials in the
United States.  There are a lot of drugs in development in oncology and it
seems to be easier now to get patients accrued on the trials if one goes
(ex-US).

This is a practice that most pharmaceutical companies are actually taking on
and the FDA is quite comfortable with this.  The FDA has been approving drugs
based on data that has been obtained from countries other than the United
States and they're very comfortable with that at this point.

So I think that we're doing trials initially in Europe because that's where
we can get patients accrued quickly and we can get answers to some of the
questions quickly so that we can move on to more advanced stages of testing.

However, we would expect that the pivotal trials would also be conducted in
the United States because the United States is really, I think, where the
oncology market has really been predominantly.  Usually, we follow those
very closely with approvals in Europe.

So, you know, looking very far in the future, you know, if everything goes
well, that's how we would see it happening, but I don't want you to confuse
the fact that we're doing trials (ex-US) initially with that - that is our
focus for the market.

(Bill Dawkins): Okay, thank you very much.

Rosemary Mazanet: Thank you.

Operator: Ladies and gentlemen, as a reminder, to register for a question,
please press the 1 followed by the 4 on your telephone.

Our next question comes from the line of (Jim Crenna) from MJSK.  Please
proceed with your question.

(Jim Crenna): Good morning, Rosemary.

Rosemary Mazanet: Good morning, (Jim).

(Jim Crenna): I've got a lot of questions and I'm only going to ask two.

The first one is, talk about the clinicals.  I think a lot of people, when
they hear clinicals, they think it's a three, four-year, 500 to 700 patients,
you know, like a Phase III, but are you looking at 40 or 50 patients in a
Phase II?

Are you looking at a year to 18 months in open trials where information
will come out as doses go on?  Could you just explain and kind of the cost
to those clinical - the ovarian?

Rosemary Mazanet: The clinical trial that we're planning to do first, is
exactly as you described, it's about 40 patients.  It should be completely
wrapped up within 18 months, perhaps sooner.

We will have access to that data on an ongoing basis.  And so, you know,
the goal of this, as in most Phase II work, is really to learn about your
drug so that you can design the correct Phase III.

So, you know, as I mentioned in the Phase I, the patients didn't get
pre-medicated for side effects and they didn't get a lot of hydration,
you know, we will be sure to take those steps in this trial so that, you
know, the toxicities are minimal and minor, so that patients can get
repeated dosing through cycles without increasing the toxicity and
you know, the best schedule for giving the drug.  Although we think that
that will be pretty similar to other platinum drugs.

So yes, this is what we're envisioning.  You know, this isn't going to be a
sort of a black box where we're doing a large randomized trial right now.
And I think what we're looking for is the best way to differentiate this
product from other platinum products.

Once we know more about that, if the - you know, how the efficacy stacks up
and how the toxicity stacks up, then we'll be in a position to know a little
more about what we'll need for a registration trial.

If the drug is clearly differentiatable, okay, from existing therapies, then,
you know, obviously it might have an easier Phase III program with, you know,
fewer patients than the hundreds that you would describe.  But again, that
all remains to be seen and it's a process.

You may have asked another question in there, I apologize -

(Jim Crenna): Cost, cost.

Rosemary Mazanet: - if I missed it.

(Jim Crenna): The estimated cost.

Rosemary Mazanet: Oh, the estimated cost.

The good thing about this, there's another advantage to doing things (ex-US),
is that the investigators and sites have less inherent overhead in their
systems.  You know, we're expecting that this Phase II that I've outlined
will cost us about 1.2 million to complete.

(Jim Crenna): Okay.

Rosemary Mazanet: And you know, there's additional pre-clinical work that we're
doing with regard to scaling up manufacturing and things, but you know, this
is - we're very happy that we think we're able to do this with a very good
(CRO) group and that - will do it for a much less money than we would if we
were doing this in the States.

Jim Crenna): So, given that it's an open trial and it's only 40 patients and
I don't know how quickly you can sign up these patients depending upon
competition for patients, but since you're already talking to potential
licensing partners, you know, three to six months down the road, you have
10, 12, 15 people (dose) and you're getting, you know -- let's hope you get
some positive results -- is, first of all, that should enhance the value of
a license and I think that's why you're starting (to say this towards)
yourself.

But secondly, if you only had equal efficacy and I know oxaliplatine's not
used in ovarian yet, and if we do call a (rectal) that's where you really -
with a combination trial, but the toxicity, the neuro-toxicity that
oxaliplatine seems to exhibit, on a humanitarian type of situation, if you
just got rid of the toxicity and had equal efficacy, is that enough to make
this drug, you know, pretty much trump oxaliplatine?

Rosemary Mazanet: You know, the FDA is hard to predict.  I think that no one
would find fault with that statement.  But certainly, there are other
situations where drugs that are commonly used have been, you know,
superseded in the market by drugs that were similar in efficacy, but
less toxic has come along.

So I think that there is a role for that.

The thing that really struck me was in the recent past, some physician advisory
groups have recommended that oxaliplatine can be given to patients with colon
cancer who has had all of their cancer removed, but they had some nodes and
things that were also removed but they are at a higher risk for relapse.
This is called adjuvant therapy when they get chemotherapy, even though
they don't have evidence of active disease at the time.

So this group of physicians has recently said that oxaliplatine could be used
in those patients.  Now, the thing about those patients is, those patients
are presumably cured.  You're not trying to get a response, these are
presumably cured patients.

So one would think that, you know, certainly you would want to minimize toxicity
in a patient group like that.

(Jim Crenna): Right.

Rosemary Mazanet: Again, I don't know, you know, what the FDA will want to see,
I can't really predict that right now.  But, you know, I can see we're
certainly having less toxicity in patients that are - that you're curing of
disease, you know, it sounds like a very good idea.

(Jim Crenna): Okay, that was my first question, real quickly, here's the
second topic.

Given that you should be pretty much out of harm's way on the balance sheet
and hopefully that restructuring will be taken care of very soon, don't you
think that the market capital of this company was a potential of not only
AP5346, because a lot of people think you're a one-trick pony now, but these
different delivery systems that deliver all potential types of drugs,
targeted drug delivery, that this thing is so undervalued compared to other,
you know, small biotech companies out there, you know, I'm not going to ask
you what you think it should be valued unless you want
to offer us an opinion, but don't you think we're utterly undervalued?

Rosemary Mazanet: Well I, you know, I think that you're right to point out
that there are many things besides the platinum drug that are a value at
Access Pharmaceuticals and I appreciate your having done that.

I think that, you know, there are companies that just have one of these
technologies that, you know, are publicly traded, if you want to look at
comps, okay.  You know, so we have a number of things.

What the company hasn't been able to do because, you know, again, we had so
many very different, different businesses under the same roof, we weren't
really able to focus on developing any of these additional products that
would be used for, you know, systemic delivery for therapeutics; and now
we can.

So, you know, hopefully, we can do a little bit more work and get a lot of
gain.  And that's always the goal with these early projects, is, you know,
hopefully we can get some proof of principle pretty early and some of this
is with our collaborators, obviously.  But, you know, then - and people can
see the value.

(Jim Crenna): Thank you very much.

Operator: Our next question comes from the line of (Dorin Frai),
private investor. Please proceed with your question.

(Dorn Frai): Good morning.

Rosemary Mazanet: Good morning.

(Dorin Frai): Over last two to three years, there were a number of
collaborations and we really didn't receive much of an update in terms of
progress or the discussions, any perspective of, you know, licenses or,
could you elaborate on that for us, please?

Rosemary Mazanet: Do you mean on the oral healthcare business or on the
technology business or -

(Dorin Frai): There were - for nanoparticle, there were several, like three
collaborations that I recall that were announced.  Some, the names were
withheld for competitive reasons, I guess, it's just that we don't have
too much of an update on those programs.

Rosemary Mazanet: Right.  What I can tell you is for the technologies that
Access Pharmaceuticals continues to have and manage, we do have some
collaborations that were actually announced last May and those are still
very early.  So we really don't have anything to report on that.  That's
on Vitamin B12 nanoparticle.

There are a number of collaborations that now will be managed by Uluru and
you know, I think that it's appropriate to get updates on those from them.

But, you know, that's really about all I can say right now.  It's too early
to give any updates on our collaborations that began in May.

(Dorin Frai): Okay.  Thank you very much.

Rosemary Mazanet: Sure.

Operator: There are no further questions at this time.

Donald Weinberger: Well, we thank everybody for participating.  And again, to
underscore what Rosemary said, for your patience and support, we're excited
about what lies ahead and the focus we have now as a company.  We're pleased
with this sale, we're pleased for Kerry, he knows this area, and we wish him
well in that endeavor.

So thank you all for your support, we'll look forward to updating you again.

Operator: Ladies and gentlemen, that does conclude the conference call
for today.  We thank you for your participation and ask that you please
disconnect your lines.  Have a great day everyone.

END